Global Rheumatoid Arthritis Market To Observe Robust Growth Through 2026

May 09, 2022

According to the industry analysis report titled ‘Global Rheumatoid Arthritis Market (2021 Edition) - Analysis By Drug Type (NSAIDs, DMARDs, Corticosteroids, Others), Treatment, Diagnosis, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)’ available with MarketStudyReport, global rheumatoid arthritis market was worth USD 24.46 billion in 2020 and is expected to observe robust growth during 2021-2026.

The rising geriatric & tobacco smoking population and surging investments for individual researchers & academic institutions are the key factors driving the growth of global rheumatoid arthritis market. Moreover, initiatives taken by WHO and NIH for the prevention and treatment of chronic disorders will augment the overall industry outlook as well.

Request sample copy of this report:

Based on drug type, the market is further segmented into DMARDs (Disease-modifying anti-individual researchersrheumatic drugs), NSAIDs (non-steroidal anti-inflammatory drugs), Corticosteroids, and others.

Among these, the DMARDs segment is estimated to hold the largest market share over the forecast period, owing to the rising prevalence of rheumatoid arthritis diseases, increasing launch of therapeutic agents, and favorable reimbursement policies for the high-cost treatment products.

Moving on to treatment type, global rheumatoid arthritis marketplace is further divided into joint fusion, tendon repair, joint replacement, and others. As per diagnosis type, the industry is fragmented into ESR (Erythrocyte Sedimentation Rate), CRP (Creative Protein Test), and others.

Regionally, Americas accounted for the largest market share in 2020 and is expected to expand substantially over the analysis period, owing to the presence of a large patient base, availability of well-developed infrastructure, rising awareness regarding disease treatment, and high adoption of biopharmaceuticals for treatment.

The leading companies operating in the global rheumatoid arthritis market include Merck KGaA, Eli Lilly Company, Bristol-Mayor Squibb, Johnson & Johnson, Pfizer Inc., Gilead Sciences Inc., Sanofi S.A., Amgen Inc., F. Hoffman-La Roche Ltd., Cipla Limited, and Galapagos N.V.

Chat with us